Bacil Pharma Ltd - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24200MH1987PLC043427 Incorporated 08 May 1987 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - BSE: 524516 Public Limited Company pharma
Market Cap
₹23.27 Cr
BACPHAR · BSE
Share Price
₹16.70
+3.02% today
EBITDA
−₹0.24 Cr
FY 2025-26
Net Profit
₹1.57 Cr
FY 2025-26 · +1307.7% YoY
P/E (TTM)
15.5x
P/B 1.0x
ROE
6.2%
ROCE 3.9%
Authorised capital
₹20 Cr
Registered with MCA
Paid-up capital
₹14.35 Cr
Issued & subscribed

About Bacil Pharma Ltd

Data last updated:

Bacil Pharma Ltd is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 08 May 1987 and has been in existence for over 39 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24200MH1987PLC043427. The company has 1 GST registration on record, which is no longer active. It is a listed company as per MCA records. Its shares are listed on BSE: 524516.

The company has an authorised share capital of ₹20 Cr and a paid-up capital of ₹14.35 Cr. It is led by directors including Chaitali Kalpataru Shah and Omprakash Pyarelal Sonar.

Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.

The net worth stands at ₹24.81 Cr (down 2.4% YoY). Total assets are valued at ₹24.81 Cr (down 3.1% YoY).

The company is associated with 1 brand: Bacil Pharma. Court records list 3 cases involving the company, including 3 filed against it. The company has 57 deals on record (57 market trades); the latest was in September 2026. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Medipex Pharmaceuticals India Private Limited with revenue of ₹66.81 Lakh.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bacilpharma.com.

Company details

CIN L24200MH1987PLC043427
Registration Number 043427
Incorporation Date 08 May 1987
ROC Mumbai
Listing Status Listed - Listed on BSE (524516)
Company Status Active
Compliance Status Active Compliant

Contact details

Bacil Pharma Ltd's registered office is in Mumbai, Maharashtra. Its website is bacilpharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    Office G2/G3 Samarpan Complex Next To Mirador Hotel, Link Road Opp Satam Wadi Chakala Sahar Andheri (East), Mumbai, Maharashtra, India – 400099
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Bacil Pharma Ltd, buy the company report.

Comprehensive company report
Bacil Pharma Ltd - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Bacil Pharma operates one associated brand: Bacil Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Manufacturer of drugsbacilpharma.com

Financials of Bacil Pharma Ltd

FY 2025-26 filings available

Bacil Pharma Ltd reported revenue of ₹- for FY 2025-26.

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹0.00 Cr
EBITDA
−₹0.24 Cr
+4.0% YoY
Profit After Tax
₹1.57 Cr
+1307.7% YoY
Net Worth
₹24.81 Cr
-2.4% YoY
Total Assets
₹24.81 Cr
-3.1% YoY
Total Debt
Nil

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue0.000.000.000.000.000.000.00
EBITDA(0.24)(0.25)(0.18)(0.22)(3.91)(0.30)(0.43)
Profit before tax1.000.41(0.05)(0.11)(3.85)(0.23)(0.31)
Net profit1.57(0.13)(0.15)(0.16)(0.09)(0.09)(0.05)
EPS (₹)1.110.29(0.09)(0.16)(5.91)(0.37)(0.48)
Balance sheet
Total assets24.8125.601.311.121.261.571.56
Net worth24.8125.431.221.101.231.391.39
Total debt0.000.160.100.020.030.180.17
Cash & bank0.572.860.040.030.230.100.04
Net working capital(0.83)2.900.030.030.23(2.36)(2.45)
Cash flow
Cash from operations0.710.400.00(0.15)(4.01)(0.40)(0.38)
Cash from investing(2.38)0.340.08(0.12)3.810.530.39
Cash from financing(0.62)2.08(0.06)0.060.33(0.07)(0.06)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue0.000.000.000.000.000.000.000.00
Other income0.090.090.110.060.051.000.090.00
Total expenses0.060.020.070.030.040.110.070.06
EBITDA(0.06)(0.02)(0.07)(0.03)(0.04)(0.11)(0.07)(0.06)
Depreciation0.000.000.000.000.000.000.000.00
Interest0.000.000.000.000.000.000.000.00
Profit before tax0.030.070.040.030.010.890.02(0.06)
Tax0.040.08(0.58)0.000.000.220.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 19 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue0.000.000.000.000.000.000.000.00
Other income0.090.090.110.060.051.000.090.00
Total expenses0.060.020.070.030.040.110.070.06
EBITDA(0.06)(0.02)(0.07)(0.03)(0.04)(0.11)(0.07)(0.06)
Depreciation0.000.000.000.000.000.000.000.00
Interest0.000.000.000.000.000.000.000.00
Profit before tax0.030.070.040.030.010.890.02(0.06)
Tax0.040.08(0.58)0.000.000.220.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue0.000.000.000.000.000.000.00
Other income1.240.660.130.110.060.070.14
Total expenses0.240.250.180.223.910.300.43
Employee cost0.050.140.100.090.060.050.09
EBITDA(0.24)(0.25)(0.18)(0.22)(3.91)(0.30)(0.43)
Depreciation0.000.000.000.000.000.000.01
Interest0.000.000.000.000.000.000.01
Profit before tax1.000.41(0.05)(0.11)(3.85)(0.23)(0.31)
Tax(0.57)0.000.000.000.000.000.00
Net profit1.57(0.13)(0.15)(0.16)(0.09)(0.09)(0.05)
EPS (₹)1.110.29(0.09)(0.16)(5.91)(0.37)(0.48)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital13.9713.976.536.536.536.536.53
Reserves & surplus10.8411.46(5.31)(5.43)(5.30)(5.14)(5.14)
Shareholders' funds (net worth)24.8125.431.221.101.231.391.39
Secured loans0.000.000.000.000.030.180.17
Unsecured loans0.000.160.100.020.000.000.00
Total debt0.000.160.100.020.030.180.17
Total liabilities24.8125.601.311.121.261.571.56
Assets
Gross block0.000.000.060.060.062.562.56
Net block0.000.000.010.010.012.522.52
Capital work in progress0.000.000.000.000.000.000.00
Investments24.2421.360.610.430.310.370.43
Inventories0.000.000.000.000.000.000.00
Sundry debtors1.180.000.000.000.000.000.00
Cash & bank balances0.572.860.040.030.230.100.04
Loans & advances0.000.050.010.010.010.060.06
Total current assets1.752.910.050.040.240.160.10
Total current liabilities2.580.010.020.010.012.522.55
Net working capital(0.83)2.900.030.030.23(2.36)(2.45)
Total assets24.8125.601.311.121.261.571.56
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2.860.040.030.230.100.040.09
Net cash from operating activities0.710.400.00(0.15)(4.01)(0.40)(0.38)
Net cash from investing activities(2.38)0.340.08(0.12)3.810.530.39
Net cash from financing activities(0.62)2.08(0.06)0.060.33(0.07)(0.06)
Net change in cash(2.29)2.820.01(0.20)0.130.06(0.05)
Closing cash0.572.860.040.030.230.100.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
EBITDA growth+4.0%-38.9%+18.2%+94.4%-1203.3%+30.2%-
PBT growth+143.9%+9998.0%+54.6%+97.1%-1573.9%+25.8%+13.9%
Net income growth+1307.7%+13.3%+6.3%-77.8%0.0%-80.0%-
EBITDA CAGR (3Y)+2.9%-60.0%-15.7%-20.0%+107.1%-57.8%+36.3%
Profitability & leverage
Return on capital employed+3.9%-1.0%0.0%0.0%0.0%0.0%0.0%
Return on net worth+6.2%-1.1%0.0%0.0%0.0%0.0%0.0%
Debt / equity0.000.010.050.020.080.130.08
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover0.000.000.000.000.000.00-2.27
Efficiency & per share
Fixed asset turnover0.000.000.000.000.000.000.00
Inventory turnover0.000.000.000.000.000.000.00
Debtors turnover0.000.000.000.000.000.000.00
EPS (₹)1.110.29(0.09)(0.16)(5.91)(0.37)(0.48)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)17.7618.201.861.681.882.132.12

To see the full year-wise statements and ratios of Bacil Pharma Ltd, buy the company report.

Board of directors of Bacil Pharma Ltd

Bacil Pharma has 3 current directors and 17 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Chaitali Kalpataru ShahAdditional Director16 Jul 20251 Years 4 MonthsCurrent
Omprakash Pyarelal SonarAdditional Director30 Jun 20260 Years 4 MonthsCurrent
Vivek Mukesh YadavAdditional Director30 Jun 20260 Years 4 MonthsCurrent

Peer comparison

Bacil Pharma Ltd is compared with the 10 companies closest to it by revenue in the Pharma industry (Formulations), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Medipex Pharmaceuticals India Private Limited₹66.81 Lakh (FY 2025)53175.0%Mumbai, Maharashtra, India
Ferico Pharma (India) Pvt Ltd₹66.61 Lakh (FY 2025)6.0%Navi Mumbai, Maharashtra, India
Ruso Pharma Private Limited₹66.5 Lakh (FY 2025)-5.0%Navi Mumbai, Maharashtra, India
Membrane Pharma India Private Limited₹66.29 Lakh (FY 2025)44.0%Gurugram, Haryana, India
Greenenvy Healthcare Private Limited₹66.19 Lakh (FY 2025)-71.0%Mangalore, Karnataka, India
G and B Pharmaceuticals Private Limited₹65.84 Lakh (FY 2023)294.0%Jagadhri, Haryana, India
Calsita Futuristic Private Limited₹65.57 Lakh (FY 2025)91.0%Vadodara, Gujarat, India
Nunchi Pharma Private Limited₹65.56 Lakh (FY 2025)3.0%Delhi, India
Kancare Pharmaceuticals Private Limited₹65.29 Lakh (FY 2023)1596.0%Roorkee, Uttarakhand, India
Hindustan Pharmatech Private Limited₹65.21 Lakh (FY 2025)-34.0%Mumbai, Maharashtra, India

To see the full peer comparison of Bacil Pharma Ltd, buy the company report.

Auditor

Bacil Pharma Ltd is audited by Laxmikant Kabra & Co. LLP for the financial year 2023.

Auditor firmFinancial yearFirm registration number
Laxmikant Kabra & Co. LLPFY 2023117183W

Shareholding

Shareholding for the quarter ended Mar 2026: promoters hold 0.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 100.00%.

Retail & Others: 100.00%
Mar 2026
QUARTER
100.00% Retail & Others
Promoter holding - history
Now 0.00% · Mar 2026High 0.20% · Jun 2025Low 0.00% · Mar 2026
0%0.5%1%1.5%2%Jun 2025Sep 2025Dec 2025Mar 2026Jun 2025: 0.20%Sep 2025: 0.10%Dec 2025: 0.10%Mar 2026: 0.00%0.20%0.00%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025
Promoters0.00%0.10%0.10%0.20%
Public100.00%99.90%99.90%99.80%

Deals & funding

Bacil Pharma Ltd has 57 deals on record (57 market trades); the latest was in September 2026.

Total deals
57
Market trades
57

Deals on record (5 of 57)

WhenDealAmountParties
Sep 2026Market trade₹34.8 LakhBuyer: Shrynax Trading Private Limited
Aug 2026Market trade₹9.9 LakhBuyer: Brenley Engineers Private Limited
Aug 2026Market trade₹1.17 CrBuyer: Jr Seamless Private Limited , 3 individuals
Seller: MNM Stock Broking Private Limited , 3 individuals
Jul 2026Market trade₹27.6 LakhBuyer: Spextra Multibiz Private Limited
Seller: Spextra Multibiz Private Limited
Jul 2026Market trade₹1.16 CrBuyer: MNM Stock Broking Private Limited , Amnesti Multiservices Private Limited , Silver Stone Capital
Seller: Amnesti Multiservices Private Limited , an individual

To see the full deal history of Bacil Pharma Ltd, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Bacil Pharma Ltd; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Bacil Pharma has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.

Total GSTINs
1
Cancelled / inactive
1

To see the full GST registrations and return filing status of Bacil Pharma Ltd, buy the company report.

Recent activity

Bacil Pharma Ltd has 27 board changes on record since 1990: 16 appointments and 11 cessations. The latest: Omprakash Pyarelal Sonar was appointed as Additional Director on 30 Jun 2026.

Appointed
Omprakash Pyarelal Sonar was appointed as Additional Director.
Appointed
Vivek Mukesh Yadav was appointed as Additional Director.
Filing
Bacil Pharma Ltd has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
AGM
Bacil Pharma Ltd last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Ceased
Ganpat Dhondu Salekar ceased to be Manager.
Ceased
Prakash Bhoorchand Shah ceased to be Director.
Appointed
Chaitali Kalpataru Shah was appointed as Additional Director.
Ceased
Jayesh Ramchandra Patil ceased to be CFO.
Ceased
Mehul Hasmukhbhai Shah ceased to be Director.
Ceased
Lalit Jain ceased to be Director.
Ceased
Shirish Suryakant Shetye ceased to be Director.
Appointed
Mehul Hasmukhbhai Shah was appointed as Director.

18 earlier events are in the company report.

Frequently asked questions

Bacil Pharma is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 08 May 1987 (39+ years old) and is registered under CIN L24200MH1987PLC043427. Listed on BSE: 524516.

Bacil Pharma has 3 current directors:

The latest financial statements of Bacil Pharma on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.

No. Bacil Pharma has 1 GST registration on record and it is cancelled or inactive.

The CIN (Corporate Identification Number) of Bacil Pharma is L24200MH1987PLC043427. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Bacil Pharma is a listed company as per MCA records. Its shares are listed on BSE (code: 524516).

Bacil Pharma has 3 court cases on record: 3 filed against it.

Bacil Pharma was incorporated on 08 May 1987, making it 39+ years old. It is registered with the Registrar of Companies, Mumbai.

Bacil Pharma has 57 deals on record (57 market trades); the latest was in September 2026.

The peers of Bacil Pharma by revenue are Medipex Pharmaceuticals India Private Limited, Ferico Pharma (India) Pvt Ltd, Ruso Pharma Private Limited, Membrane Pharma India Private Limited, Greenenvy Healthcare Private Limited and 5 more, all in the Pharma industry (Formulations).

Omprakash Pyarelal Sonar was appointed as Additional Director on 30 Jun 2026. Vivek Mukesh Yadav was appointed as Additional Director on 30 Jun 2026. Ganpat Dhondu Salekar ceased to be Manager on 12 Aug 2025. Bacil Pharma has 27 board changes on record in total.